Clinical Trials

Below is a listing of clinical trials conducted at MUSC Hollings Cancer Center. Use the tools in the left toolbar to refine your search. If you are interested in Early Phase/Multi Tumor trials, select the program “Phase I Unit.” Please note that cohort information for the Phase I trials changes often.

Clinical Research Group Intranet
Hold Ctrl (Cmd on Mac) to select multiple.
Protocol Title Status Docs
104225 An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer. OPEN TO ACCRUAL

104333 A Phase II Randomized Trial of Neoadjuvant Chemotherapy or Chemo-Immunotherapy in Patients with Recurrent/Persistent PD-L1 Enriched Squamous Cell Carcinoma of the Head and Neck Undergoing Salvage Surgery (NEOPOLIS) OPEN TO ACCRUAL

104250 A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy OPEN TO ACCRUAL

104270 Omission of Post-Operative Radiation in Patients with Intermediate Pathological Risk Features and Negative Two Week Post-Operative ctHPVDNA (OPERATION Trial) OPEN TO ACCRUAL

104177 A Phase III, Open-Label, Multi-Center, Randomized Study Comparing AAA817 Plus ARPI Versus Standard of Care in Adult Participants with PSMA-Positive Metastatic Castration Resistant Prostate Cancer OPEN TO ACCRUAL

104156 A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-nave Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL) OPEN TO ACCRUAL

104241 A Phase 1a/1b Study of NRM-823 as Monotherapy and in Combination with Immune Checkpoint Inhibition in Participants with Locally Advanced or Metastatic Refractory Solid Tumors OPEN TO ACCRUAL

104243 A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma OPEN TO ACCRUAL

104205 A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis OPEN TO ACCRUAL

104292 CA266-0008: ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination with Ipilimumab or Cabozantinib in Participants with Advanced Renal Cell Carcinoma (RCC) OPEN TO ACCRUAL

104185 A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer OPEN TO ACCRUAL

104289 A randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T-Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT) OPEN TO ACCRUAL

103565 A Phase 1a "Window Trial" on Cannabidiol (CBD) for Breast Cancer Primary Tumors OPEN TO ACCRUAL

104196 Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy OPEN TO ACCRUAL

104161 A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer OPEN TO ACCRUAL

104271 A012303: ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade OPEN TO ACCRUAL

104201 WATER IV Prostate Cancer: Aquablation versus Radical Prostatectomy for the Treatment of Localized Prostate Cancer OPEN TO ACCRUAL

104178 Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4) OPEN TO ACCRUAL

104267 NRG-GU015: The Phase III Adaptive Radiation and Chemotherapy for Muscle Invasive Bladder Cancer Trial (ARCHER) OPEN TO ACCRUAL

104263 A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or Without Cemiplimab (REGN2810) for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study) OPEN TO ACCRUAL